Momat ointment appearance. 0.1% 15g

Description

Composition
Active substance:
100 g of ointment contains: mometasone furoate – 0.1 g ;.
Excipients:
Paraffin (white soft paraffin), white beeswax, propylene glycol monostearate.
Description:
White ointment.
Product form:
Ointment for external use 0.1%.
5 g and 15 g in the aluminum tube, the nozzle having a closed end with a lid having a cutting edge for puncturing.
Each tube together with instructions for use placed in a cardboard box.
Contraindications
– Hypersensitivity to any component of the formulation or to the GCS; – rosacea, perioral dermatitis. – bacterial, viral (Herpes simplex, chickenpox, Herpes zoster), or a fungal infection of the skin; – tuberculosis, syphilis; – post-vaccination reactions; – Children under 2 years old; – pregnancy (treatment of large areas of skin, long-term care); – lactation period (used in large doses and / or for a long time).
Carefully
Applying to the skin of the face and intertriginous skin, the use of occlusive dressings, as well as the treatment of large areas of skin and / or long-term treatment (particularly in children).
Dosage
0.1%
Indications
Inflammation and itching at dermatoses (psoriasis, atopic dermatitis, seborrheic dermatitis), measurable glucocorticosteroid therapy in adults and children older than 2 years.
Interaction with other drugs
Drug interaction studies Momat ointment with other drugs have not been conducted.
Overdose
Symptoms: inhibition of function of the hypothalamic-pituitary-adrenal system, including secondary adrenal insufficiency.
Treatment: symptomatic, if necessary – electrolyte imbalance correction, removal of the drug (for long-term therapy – gradual elimination).
pharmachologic effect
Pharmacological group:
Glucocorticosteroids for local use.
Pharmacological properties:
Mometasone – synthetic glucocorticosteroid (GCS) having anti-inflammatory, antipruritic and antiexudative action. GCS induce isolation of proteins that inhibit phospholipase A2 and collectively known lipocortin which control the biosynthesis of inflammatory mediators such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid.
Pharmacokinetics:
Absorption ointment Momat insignificant. After 8 hours after the single application on intact skin (without occlusive dressings) detected in the systemic circulation of about 0.7% of active compound. Mometasone extensively metabolized in the liver, kidneys displayed mainly in the small amount in the bile. The half-life is approximately 5.8 hours.
Pregnancy and breast-feeding
Safety of application of mometasone furoate during pregnancy and lactation has not been studied.
GCS cross the placental barrier. Avoid long-term treatment and the use of large doses during pregnancy due to the risk of negative impact on fetal development.
Corticosteroids are excreted in breast milk. In the case where it is assumed the use of corticosteroids at high doses and / or for a long time, discontinue breastfeeding.
Conditions of supply of pharmacies
On prescription.
side effects
Rarely – skin irritation and dryness, burning sensation, pruritus, folliculitis, hypertrichosis, acne, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, the accession of a secondary infection, the signs of skin atrophy, striae, miliaria. Less than 1% of the cases – the formation of papules, pustules.
When applying the external forms of corticosteroids for a long time and / or for the treatment of large areas of skin, or by using occlusive dressings, especially in children and teenagers, can have side effects characteristic of systemic corticosteroids, including adrenal insufficiency and Cushing’s syndrome.
special instructions
When applied to large areas of the skin for a long time, especially when using occlusive dressings may develop systemic corticosteroids. In view of this, patients should be observed for signs of suppression of the hypothalamic-pituitary-adrenal system and the development of Cushing’s syndrome. Avoid getting Momat ointment in the eye.
Propylene glycol, a part of the drug may cause irritation at the site of application. In such cases, should stop using the ointment Momat and appropriate treatment.
Note that corticosteroids can change the manifestation of some skin diseases that can complicate diagnosis. In addition, use of corticosteroids may cause delays wound healing.
When long-term therapy of GCS sudden cessation of treatment can lead to rebound syndrome, which manifests itself in the form of dermatitis with intense redness and burning sensation. Therefore, after the long course of treatment abolition of the drug must be carried out gradually, e.g., switching to intermittent treatment regimen before it is completely stopped.
Pediatric use:
Safety and efficacy of mometasone furoate in the local application at children over a period longer than 6 weeks, were not studied.
Due to the fact that in children the value of the ratio of surface area and body weight greater than that of adults, children are at greater risk of suppression of the hypothalamic-pituitary-adrenal system and the development of Cushing’s syndrome in the application of any topical corticosteroids. Long-term corticosteroids treatment of children can lead to violations of their growth and development.
Children should receive the minimum dose sufficient to achieve the effect.
Storage conditions
In a dry, dark place at a temperature not higher than 25 ° C.
Do not freeze.
Keep out of the reach of children.
Dosing and Administration
Outwardly.
Thin layer Momat ointment applied to the affected skin once daily. The duration of treatment is determined by its efficacy and tolerability by the patient, presence and severity of side effects.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist